BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, Maekawa Y. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol. 2002;7:335-342. [PMID: 12494248 DOI: 10.1007/s101470200051] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Makino H, Uetake H, Danenberg K, Danenberg PV, Sugihara K. Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer. BMC Cancer 2008;8:210. [PMID: 18652704 DOI: 10.1186/1471-2407-8-210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
2 Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004;214:19-33. [PMID: 15331170 DOI: 10.1016/j.canlet.2004.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yasumatsu R, Nakashima T, Wakasaki T, Ayada T, Kadota H, Masuda M, Toh S, Shiratsuchi H, Komune S. Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma. Eur Arch Otorhinolaryngol 2010;267:581-6. [PMID: 19697054 DOI: 10.1007/s00405-009-1062-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J, Miyagawa S. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy. 2006;52:301-307. [PMID: 17008790 DOI: 10.1159/000096002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
5 Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006;95:607-15. [PMID: 16880781 DOI: 10.1038/sj.bjc.6603297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
6 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Nakayama G, Ohashi N, Koike M, Yamamura Y, Nakao A. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307-313. [PMID: 17303323 DOI: 10.1016/j.canlet.2007.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
7 Mori R, Futamura M, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K, Yoshida K. 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine. Oncol Lett 2017;14:3162-8. [PMID: 28927061 DOI: 10.3892/ol.2017.6512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T, Fujii Y. Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus. 2008;21:15-20. [PMID: 18197934 DOI: 10.1111/j.1442-2050.2007.00700.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
9 Barbado M, Preisser L, Boisdron-Celle M, Verriele V, Lorimier G, Gamelin E, Morel A. Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype. Cancer Lett 2006;242:168-79. [PMID: 16387426 DOI: 10.1016/j.canlet.2005.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Suetsugu T, Mori R, Futamura M, Fukada M, Tanaka H, Yasufuku I, Sato Y, Iwata Y, Imai T, Imai H, Tanaka Y, Okumura N, Matsuhashi N, Takahashi T, Yoshida K. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines. Oncol Rep 2021;45:27. [PMID: 33649846 DOI: 10.3892/or.2021.7978] [Reference Citation Analysis]
11 Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV, Sugihara K. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005;223:103-11. [PMID: 15890242 DOI: 10.1016/j.canlet.2004.09.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
12 Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 2008;61:587-94. [DOI: 10.1007/s00280-007-0511-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
13 Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007;141:346-353. [PMID: 17349846 DOI: 10.1016/j.surg.2006.06.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
14 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 167] [Article Influence: 40.6] [Reference Citation Analysis]
15 Akahoshi K, Ban D, Kuboki R, Oba A, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Orotate phosphoribosyltransferase as a predictor of benefit from S‐1 adjuvant chemotherapy for cholangiocarcinoma patients. Journal of Gastroenterology and Hepatology 2018;34:1108-15. [DOI: 10.1111/jgh.14477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Stoehlmacher J. Prediction of Efficacy and Side Effects of Chemotherapy in Colorectal Cancer. In: Dietel M, editor. Targeted Therapies in Cancer. Berlin: Springer Berlin Heidelberg; 2007. pp. 81-8. [DOI: 10.1007/978-3-540-46091-6_8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
17 Mori R, Yoshida K, Futamura M, Suetsugu T, Shizu K, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells. Gastric Cancer 2019;22:497-505. [PMID: 30276573 DOI: 10.1007/s10120-018-0881-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H, Fukushima M. Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil on Gastric Cancer Cell Lines. Oncology 2007;70:458-64. [DOI: 10.1159/000098873] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
19 Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486-1492. [PMID: 14562021 DOI: 10.1038/sj.bjc.6601335] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
20 Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226-243. [PMID: 16041392 DOI: 10.1038/sj.tpj.6500320] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
21 Gusella M, Bertolaso L, Bolzonella C, Pasini F, Padrini R. Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays. Genet Test Mol Biomarkers. 2011;15:691-695. [PMID: 21631301 DOI: 10.1089/gtmb.2011.0021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775-9827. [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
23 Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006;119:783-791. [PMID: 16557585 DOI: 10.1002/ijc.21879] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
24 Stöhlmacher J. Pharmacogenetics in Gastrointestinal Tumors. Oncol Res Treat 2005;28:435-40. [DOI: 10.1159/000086499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Yoshitomi I, Kawasaki G, Yanamoto S, Mizuno A. Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil. Oral Oncol 2006;42:880-7. [PMID: 16757204 DOI: 10.1016/j.oraloncology.2005.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ishikawa M, Miyauchi T, Kashiwagi Y. Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. BMC Cancer. 2008;8:188. [PMID: 18597678 DOI: 10.1186/1471-2407-8-188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
27 Stoehlmacher J. The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours. Annals of Oncology 2006;17:x263-8. [DOI: 10.1093/annonc/mdl271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Stoehlmacher J, Goekkurt E, Lenz H. Pharmacogenetic aspects in treatment of colorectal cancer – an update. Pharmacogenomics 2003;4:767-77. [DOI: 10.1517/phgs.4.6.767.22825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
30 Sakurai Y, Sakamoto K, Sugimoto Y, Yoshida I, Masui T, Tonomura S, Inaba K, Shoji M, Nakamura Y, Uyama I. Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma. Cancer Sci. 2006;97:492-498. [PMID: 16734727 DOI: 10.1111/j.1349-7006.2006.00200.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
31 Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer. 2004;100:723-731. [PMID: 14770427 DOI: 10.1002/cncr.11955] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
32 Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451-62. [PMID: 19467788 DOI: 10.1016/j.ctrv.2009.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
33 Kato Y, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Hiyama E, Sueda T. Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma: Impact of TS in Ampullary Carcinoma. J Surg Oncol 2011;103:663-8. [DOI: 10.1002/jso.21879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]